Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Cancer Cell
|
November 13, 2019
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai, Haibin Zhou, Renqi Xu, et al.
Journal of Medicinal Chemistry
|
November 13, 2020
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression
Jianyong Chen, Yunlong Zhou, Xuyuan Dong, et al.
Journal of Medicinal Chemistry
|
November 21, 2019
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Haibin Zhou, Longchuan Bai, Renqi Xu, et al.
Nature Communications
|
May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
Zhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Journal of Medicinal Chemistry
|
July 18, 2018
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor
Yujun Zhao, Bing Zhou, Longchuan Bai, et al.
Journal of Medicinal Chemistry
|
August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
March 1, 2026
BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, et al.
Journal of Medicinal Chemistry
|
September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Cancer Research
|
February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Journal of Medicinal Chemistry
|
July 19, 2018
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin, Yang Hu, Bing Zhou, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Cancer Cell
|
November 13, 2019
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai, Haibin Zhou, Renqi Xu, et al.
Journal of Medicinal Chemistry
|
November 13, 2020
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression
Jianyong Chen, Yunlong Zhou, Xuyuan Dong, et al.
Journal of Medicinal Chemistry
|
November 21, 2019
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Haibin Zhou, Longchuan Bai, Renqi Xu, et al.
Nature Communications
|
May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
Zhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Journal of Medicinal Chemistry
|
July 18, 2018
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor
Yujun Zhao, Bing Zhou, Longchuan Bai, et al.
Journal of Medicinal Chemistry
|
August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
March 1, 2026
BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, et al.
Journal of Medicinal Chemistry
|
September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Cancer Research
|
February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Journal of Medicinal Chemistry
|
July 19, 2018
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin, Yang Hu, Bing Zhou, et al.
Page
of 7